Lipum AB — Investor Relations & Filings

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead drug candidate, SOL-116, is a humanized antibody designed to offer a unique, first-in-class mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum has successfully completed a Phase 1 clinical trial for SOL-116, which evaluated its safety and tolerability, supporting its continued development for rheumatoid arthritis (RA). The company also explores the potential application of its treatment for other inflammatory diseases with significant unmet medical needs, aiming to improve the quality of life for patients.